Issue Date: March 18, 2013
Astellas Dissolves Drug Development Pacts
Astellas Pharma has given back to Cubist Pharmaceuticals the rights to the antibiotic ceftolozane, which is currently being tested in combination with tazobactam in two Phase III studies to treat infections caused by gram-negative bacteria. Astellas, which owned the rights to develop the drug in Asia-Pacific and the Middle East, gets a $25 million up-front fee from Cubist. Astellas has also ended a cancer drug development partnership with
To view the rest of this content, please log in with your ACS ID.